NOC Surges 11% Post-Earnings as Analysts Race to Catch Up

Northrop Grumman jumped 11% over the past week to $534, more than double the median gain of 5.5% among its closest defense peers, after reporting Q3 results on October 20, and analysts who spent the previous fortnight cutting targets are now reversing course fast.

The speed of the analyst pivot is the defining fact of this week. Five firms raised targets on October 21 alone. Morgan Stanley's Kristine Liwag lifted to $765 from $745 while keeping Overweight. Baird upgraded outright to Outperform from Neutral, raising its target to $675 from $550. Guggenheim moved to $640 from $612, and BNP Paribas raised to $600 from $540. These moves stand in sharp contrast to the prior week's direction: Bernstein had cut to $556, Barclays initiated at Underweight with a $419 target, and TD Cowen trimmed to $540. The spread between the most bullish and most bearish targets on the Street is now roughly $350, which captures just how divided the fundamental debate remains. The consensus mean is $630, implying about 18% upside from current levels, but that average is being pulled in opposite directions simultaneously.

The bull-bear divide tracks a genuine operational tension. On the constructive side, the B-21 Raider and Sentinel programs are transitioning from development into production, bringing with them greater revenue visibility and a large backlog anchored by $3 billion in recent interceptor agreements. Management's 2026 guidance calls for mid-single-digit organic sales growth and around 11.3% segment margins. The bear case is equally concrete: fixed-price losses on the B-21 have already totalled roughly $2.04 billion, a January 2026 executive order curtailed share repurchases (buyback volumes are down 90% year-on-year in Q1, a four-quarter declining streak per SEC EDGAR data), and management sees only limited margin expansion through 2027 to 2028. The EV/EBITDA multiple has crept up about 0.4 turns over the past 30 days to 13.5x as the stock recovered, and the PE ratio has expanded roughly 1.3 points on the week to 17.8x. The factor profile adds nuance: EPS surprise ranks in the 75th percentile, a record of beating estimates, but the 12-month forward EPS growth score is in the 2nd percentile, meaning the Street is not forecasting meaningful acceleration from here.

Positioning in the lending market offers no signal worth acting on. Short interest is 1.6% of free float, barely changed on the week, and availability is effectively uncapped. Borrowing costs collapsed to 0.10% by October 20, down two-thirds on the week, the lowest level in the 30-day window. The options market has also normalised: the put/call ratio at 1.11 is almost exactly in line with its 20-day average of 1.11, with a z-score near zero. The spike in defensive hedging that was visible through late September, when the PCR reached 1.29, has fully unwound. Neither short sellers nor options traders are making a directional bet here.

The peer comparison adds context to the magnitude of the move. LMT gained 8.9% on the week and RTX rose 5.6%, both strong weeks by any measure. NOC outpaced both by a clear margin, suggesting the October 20 earnings reaction carried stock-specific relief rather than simply riding a defense-sector bid. The alt-data picture is sparse for operational signals: Wikipedia attention was running at a z-score of 2.69 at the start of October, indicating a spike in retail interest, though the Wikimedia data is an attention measure rather than a revenue indicator. With next earnings now scheduled for October 29, there is less than a week before the next formal data point, and the focus will shift quickly to whether Q3 results changed anything about the margin trajectory on the B-21.

The specific thing to watch is whether RBC Capital or Bernstein, both of whom hold cautious ratings with targets below the current price at $550 and $556 respectively, respond to the Q3 print with a formal revision before October 29. Their next move would crystallise whether the Street's centre of gravity has genuinely shifted or whether the target raises from October 21 reflect only the most optimistic cohort updating to reflect a better-than-feared quarter.